Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)
A Phase I Tolerance, Safety and Efficacy Study of Alkotinib in Patients With Advanced ALK Positive /ROS1 Positive NSCLC and Previously Treated With Chemotherapy or Crizotinib
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
This PHASE1 trial investigates Non-small Cell Lung Cancer and is currently completed. Suzhou Zelgen Biopharmaceuticals Co.,Ltd leads this study, which shows 12 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
May 2023 — Apr 2024 [monthly]
Recruiting PHASE1
-
Dec 2022 — May 2023 [monthly]
Recruiting PHASE1
▶ Show 7 earlier versions
-
Sep 2021 — Dec 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Feb 2020 — Aug 2020 [monthly]
Recruiting PHASE1
-
May 2019 — Feb 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2018 — May 2019 [monthly]
Not Yet Recruiting PHASE1
-
Aug 2018 — Sep 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
For direct contact, visit the study record on ClinicalTrials.gov .